Are androgen receptor agonists a treatment option in bladder cancer?

Autor: De Ieso ML; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, Australia., Aldoghachi AF; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, Australia., Tilley WD; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, Australia., Dwyer AR; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, Australia. Electronic address: amy.dwyer@adelaide.edu.au.
Jazyk: angličtina
Zdroj: The Journal of steroid biochemistry and molecular biology [J Steroid Biochem Mol Biol] 2025 Jan; Vol. 245, pp. 106623. Date of Electronic Publication: 2024 Sep 19.
DOI: 10.1016/j.jsbmb.2024.106623
Abstrakt: Sex-related differences in bladder cancer incidence and progression infer a role for sex hormones and their cognate receptors in this disease. In part due to the oncogenic role of androgen receptor signaling in prostate cancer, the focus of most preclinical and clinical research to-date has been on the potential pro-tumorigenic action of androgens in urothelial cancers. However, clinical studies of androgen receptor antagonism have yielded minimal success. In this review, we explore the tumor suppressor role of androgen receptor in bladder cancer and discuss how it might be harnessed therapeutically.
Competing Interests: Declaration of Competing Interest Michael L. De Ieso has no interests to declare. Ahmed Faris Aldoghachi has no interests to declare. Wayne D. Tilley has no interests to declare. Amy R. Dwyer has no interests to declare.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: